IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#2096
Positioning
Market Dominance
Manufacturing
Shipbuilding, Railroad Equipment
$310M
Ben M. Palmer
Marine Products Corporation designs, manufactures, and sells recreational fiberglass powerboats for the sportboat, sport fishing, and jet boat markets. The company sells its products to a network of 206 domestic and 92 international independent authorized dealers.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Dates updated upon official exchange announcement.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = MPX ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$MPX MARINE PRODUCTS CORP | 49 | 60 | 64 | 41 | 21.8x | 19.5x | 9.8% | 6.9% | 18.8% | 6.0% | 5.4% | -23.6% | 14.2% | 42.0x | $310M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
MARINE PRODUCTS CORP (MPX) receives a "Reduce" rating with a composite score of 49.4/100. It ranks #2096 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Ben M. Palmer
Chief Executive Officer
Labor Force
940
60
42
70
Audit Verdict: Average governance indicators based on financial metrics.
No recent insider transactions available for MPX
In-line with peers — no strong momentum signal
Trading at a discount to fundamentals — favorable entry valuation
Average quality profile
Low volatility — smoother ride and historically better risk-adjusted returns
Moderate investment profile
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for MPX.
View All RatingsMaterial decline in asset turnover efficiency detected
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 60 | 57 | +3NEUTRAL |
| MOMENTUM | 41 | 22 | +19ALPHA |
| VALUATION | 64 | 51 | +13ALPHA |
| INVESTMENT | 42 | 77 | -35DRAG |
| STABILITY | 70 | 65 | +5NEUTRAL |
| SHORT INT | 26 | 11 | +15ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy 9.8% (sector -2.5%)
GM 19% vs sector 43%, OM 6% vs sector 1%
Capital turnover N/A
Rev growth -24%, 10yr history
Interest coverage N/A, Net debt/EBITDA -16.5x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
MARINE PRODUCTS CORP receives a Reduce rating from our analysis, with a composite score of 49.4/100 and 2 out of 5 stars, ranking #2096 out of 7,333 stocks. MPX's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
With a quality score of 60/100, MPX shows adequate but unremarkable business quality. The company reports a return on equity of 9.8% (sector avg: -2.5%), gross margins of 18.8% (sector avg: 42.5%), net margins of 5.4% (sector avg: -0.2%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
MPX's value score of 64/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include a P/E ratio of 21.83x, an EV/EBITDA of 19.54x, a P/B ratio of 2.15x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.
With an investment score of 42/100, MPX exhibits moderate growth-oriented spending. Key growth metrics include revenue growth of -23.6% vs. a sector average of 5.9% and a return on assets of 6.9% (sector: -0.1%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.
MPX is currently showing below-average momentum at 41/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at -23.6% year-over-year, while a beta of 0.87 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
MPX shows good financial stability with a score of 70/100. Key stability metrics include a beta of 0.87 and a debt-to-equity ratio of 42.00x (sector avg: 0.2x). This suggests manageable leverage and moderate price volatility, making it appropriate for investors seeking a balance between growth potential and capital preservation.
MARINE PRODUCTS CORP's short interest score of 26/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 42.00x), small-cap liquidity risk. At $310M (small-cap), MPX carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
MARINE PRODUCTS CORP offers an attractive dividend yield of 14.2%, placing it among the higher-yielding stocks in its peer group. A yield this high can provide meaningful income, but investors should verify the payout is sustainable by examining the payout ratio, free cash flow coverage, and any history of dividend cuts.
MARINE PRODUCTS CORP is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #2096 of 7,333 overall (71st percentile). Key comparisons include ROE of 9.8% exceeding the -2.5% sector median and operating margins of 6.0% above the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While MPX currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Short Int. (26) would have the largest impact on the composite score.
EV/EBITDA 71% ABOVE SECTOR MEDIAN
ROE 497% BELOW SECTOR MEDIAN
Gross Margin 56% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate MARINE PRODUCTS CORP (MPX) as a Reduce with a composite score of 49.4/100 at a current price of $7.81. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential and elevated risk of underperformance relative to peers over the next 12 months.
The rating is primarily driven by strength in stability (70th percentile) and value (64th percentile), which together account for the majority of the composite score. All factors score above the 40th percentile, indicating no material weakness in the quantitative profile. We assign a No Moat rating (36/100), Low uncertainty, and Standard capital allocation.
Key items to watch: quarterly earnings execution and sector-level competitive dynamics. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
MARINE PRODUCTS CORP holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 49.4/100 places it at rank #2096 in our full 7,333-stock universe. At $310M in market capitalization, MARINE PRODUCTS CORP is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue contraction of -24% combined with momentum at the 41th percentile paints a cautious picture of the near-term business outlook. The market appears to be pricing in continued challenges, and a catalyst for reversal is not clearly visible from current data.
The margin cascade tells an important story: gross margins of 19% (-23.7pp vs sector) narrow to operating margins of 6% (+4.7pp vs sector) and net margins of 5.4%, yielding a gross-to-net conversion rate of 29%. This conversion rate is typical for the sector, suggesting a standard cost structure without notable efficiency advantages or disadvantages.
At a current price of $7.81, MARINE PRODUCTS CORP is trading near fair value based on current fundamentals. Our value factor score of 64/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. Valuation metrics are mixed, with no strong signal of mispricing in either direction.
The stock currently trades at a P/E of 21.8x (roughly in line with the sector median of 22.3x), EV/EBITDA of 19.5x (at a premium), P/B of 2.1x, P/S of 1.2x. The below-sector P/E suggests possible undervaluation or the market pricing in near-term headwinds.
A 14.21% dividend yield provides income while you wait, and dividends historically account for a significant portion of total equity returns.
The Reduce rating (composite 49.4/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Revenue decline of -24% signals business deterioration — declining revenues make it difficult to grow into the current valuation and often precede further negative revisions.
We assign a Low uncertainty rating to MARINE PRODUCTS CORP. The company exhibits strong financial stability with a beta of 0.87, conservative leverage (42% D/E), and a stability factor in the 70th percentile. The predictable nature of the business model and solid financial position reduce the range of potential outcomes, giving us confidence in our fair value estimate.
We identify no major risk factors at this time. The company's stability factor sits at the 70th percentile with quality at the 60th percentile, both of which support our low-risk assessment. The absence of material leverage, profitability, or volatility concerns reduces the likelihood of a permanent capital loss scenario.
Key risk mitigants include: above-average stability (70th percentile) suggests predictable business dynamics; a 14.21% dividend yield anchors total return. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile is favorable for long-term investors.
We rate MARINE PRODUCTS CORP's capital allocation as Standard. Management has shown adequate — though not exceptional — stewardship of shareholder capital. Returns on equity stand at 9.8%, and the balance sheet is managed within acceptable parameters (D/E: 42%). Exemplary allocators typically sustain ROE above 20% and D/E below 50%; MARINE PRODUCTS CORP falls short on at least one dimension.
There is room for improvement in optimizing the capital structure or enhancing shareholder returns. The 14.21% dividend yield provides some income return, but the overall capital allocation framework would benefit from either higher reinvestment returns, improved balance sheet efficiency, or increased shareholder distributions. We will monitor for signs of strategic improvement that could warrant an upgrade.
In summary, MARINE PRODUCTS CORP receives a Reduce rating with a composite score of 49.4/100 (rank #2096 of 7,333). Our quantitative framework assigns a No Moat (36/100, trend: stable), Low uncertainty, and Standard capital allocation. The average factor score across quality, value, momentum, stability, and investment is 55/100.
Our analysis does not support a constructive view on MARINE PRODUCTS CORP at this time. The combination of limited competitive advantages, low uncertainty, and standard capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign MARINE PRODUCTS CORP a meaningful economic moat, scoring 36/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, financial resilience, reached only 12/20.
The strongest moat sources are financial resilience (12/20) and margin superiority (10.5/20). Interest coverage N/A, Net debt/EBITDA -16.5x. GM 19% vs sector 43%, OM 6% vs sector 1%. These pillars form the core of MARINE PRODUCTS CORP's competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (0/20) and growth durability (6.2/20). Capital turnover N/A. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect MARINE PRODUCTS CORP's moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include declining revenues (-24%) that pressure the earnings outlook. The margin cascade from 19% gross to 6% operating to 5.4% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality is adequate though not exceptional, with the quality factor at the 60th percentile.
The margin profile shows gross margins of 19%, operating margins of 6%, net margins of 5.4%. Return metrics include ROE of 9.8% and ROA of 6.9%. Relative to the Manufacturing sector, gross margins are 23.7 percentage points below the sector median of 43%, and ROE of 9.8% compares to a sector median of -2.5%.
The balance sheet reflects moderate leverage with D/E of 42%, a dividend yield of 14.21%, revenue growth of -24%. The sector median D/E is 0%, putting MARINE PRODUCTS CORP at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Above 50MA
37.18%
Net New Highs
+51081

Monteverde & Associates PC, a class action law firm, is investigating four merger and acquisition transactions: MasterCraft Boat Holdings' merger with Marine Products Corporation, SunOpta's sale to Pegasus BidCo B.V., Marine Products' sale to MasterCraft, and SkyWater Technology's sale to IonQ. The firm is seeking shareholders who have concerns about these proposed transactions.
Sport boat manufacturer MasterCraft (NASDAQ:MCFT) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 13.2% year on year to $71.76 million. Its non-GAAP profit of $0.29 per share was 76.5% above analysts’ consensus estimates.

Marine Products Corporation reported a 33% year-over-year decrease in Q4 2024 net sales to $47.8 million, with net income down 21% to $4.3 million. The company cited continued soft order flow and high dealer inventories, but expects sales comparisons to be flat in the near-term with potential for growth in the second half of 2025.

Shares of Humana Inc. (NYSE: HUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2024 guidance. The company reported a Q4 adjusted loss of 11 cents per share, a turnaround from EPS income of $1.97 per share a year ago, missing the consensus for a loss of 5 cents per share. The insurer reported adjusted revenue of $25.73 billion, compared to $21.30 billion a year ago and the consensus of $25.55 billion. Humana shares dipped 11.3% to $356.93 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Onconetix, Inc. (NASDAQ: ONCO) shares surged 137% to $0.3519 after falling over 4% on Wednesday. Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) gained 97% to $4.0527 after the company announced the completion of the safety tolerability evaluation in its Phase 1b trial of Next Generation Capecitabine. Enviva Inc. (NYSE: EVA) climbed 47.4% to $0.5239. Vera Therapeutics, Inc. (NASDAQ: VERA) shares jumped 46% to $24.84 after the company announced 72-week data from the OLE period of its Phase 2b ORIGIN clinical trial. Also, Oppenheimer initiated coverage on the stock with an Outperform rating and announced a $26 price target. Rail Vision Ltd. (NASDAQ: RVSN) gained 43.8% to $7.78. Foresight's affiliate Rail Vision's Main Line System secured EU Railway Standards approval and certifications. LAVA Therapeutics N.V. (NASDAQ: LVTX) rose 37.4% to $2.13 after the company announced a clinical trial collaboration and supply agreement with Merck & Co. to evaluate LAVA-1207 in combination with KEYTRUDA. Acutus Medical, Inc. (NASDAQ: AFIB) shares climbed 30.6% to $0.29. Acutus Medical has been granted European patent number EP3043701 titled "Devices and Methods for Determination of Electrical Dipole Densities on a Cardiac Surface (And Methods for Diagnosing Tissue Health)." Prairie Operating Co. (NASDAQ: PROP) gained 28.8% to $8.17. American Superconductor Corporation (NASDAQ: AMSC) shares climbed 28.4% to $12.52 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter revenue guidance above estimates. CCSC ...
Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash. Eargo, Inc. (NASDAQ: EAR) shares climbed 50.4% to $2.5274 after the company announced it will be taken private by Patient Square Capital. VYNE Therapeutics Inc. (NASDAQ: VYNE) gained 39.9% to $3.1399 after the company announced a private placement of $88 million and data from its Phase 1b trial evaluating once-daily dosing of VYN201 in patients with nonsegmental vitiligo. Conduit Pharmaceuticals Inc. (NASDAQ: CDT) shares gained 27.9% to $1.3042 after falling more than 12% on Friday. HeartCore Enterprises, Inc. (NASDAQ: HTCR) surged 24% to $0.7718. Heartcore Enterprises recently entered into at-market offering agreement for an at-market offering with H.C. Wainwright & Co. ImmunityBio, Inc. (NASDAQ: IBRX) gained 19.4% to $2.9600. The FDA recently accepted ImmunityBio's resubmission of its Biologics License Application for N-803 as complete. Coherus BioSciences, Inc. (NASDAQ: CHRS) shares climbed 16.8% to $3.0850. Coherus and Junshi Biosciences reported FDA approval of LOQTORZI in all lines of treatment for recurrent or metastatic nasopharyngeal carcinoma. Aemetis, Inc. (NASDAQ: AMTX) gained 16.5% to $5.02. Aemetis received $150 million biodiesel supply allocation from India oil marketing companies. JinkoSolar Holding Co., Ltd. (NYSE: JKS) surged 16% to $30.01 following better-than-expected quarterly results. Akerna Corp. (NASDAQ: KERN) jumped 16% to $0.3550. MeiraGTx Holdings plc (NASDAQ: MGTX) rose 16% to $4.29. MeiraGTx announced a $30 million strategic investment from Sanofi via purchase of 4 million shares at $7.50 per share. Motus GI ...